Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - Inhibitor Therapeutics, Inc. | d328204d10k.htm |
| EX-31.2 - EXHIBIT 31.2 - Inhibitor Therapeutics, Inc. | d328204dex312.htm |
| EX-23.1 - EXHIBIT 23.1 - Inhibitor Therapeutics, Inc. | d328204dex231.htm |
| EX-32.1 - EXHIBIT 32.1 - Inhibitor Therapeutics, Inc. | d328204dex321.htm |
| EX-31.1 - EXHIBIT 31.1 - Inhibitor Therapeutics, Inc. | d328204dex311.htm |
| EX-13.1 - EXHIBIT 13.1 - Inhibitor Therapeutics, Inc. | d328204dex131.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Commonwealth Biotechnologies, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2011 as filed with the Securities and Exchange Commission on April 16, 2012 (the “Report”), I, Vincent McNelley, Acting Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| April 16, 2012 | /s/ Vincent McNelley | |||
| Vincent McNelley Acting Principal Financial Officer and Acting Principal Accounting Officer | ||||